Evoke Pharma, Inc. (EVOK)
- Previous Close
3.1000 - Open
3.2100 - Bid 2.2200 x 200
- Ask 4.0500 x 200
- Day's Range
3.1300 - 3.2100 - 52 Week Range
1.9400 - 12.3200 - Volume
5,466 - Avg. Volume
20,050 - Market Cap (intraday)
4.688M - Beta (5Y Monthly) 0.16
- PE Ratio (TTM)
-- - EPS (TTM)
-2.8100 - Earnings Date May 15, 2025 - May 21, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.00
Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is based in Solana Beach, California.
www.evokepharma.com3
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: EVOK
View More
Performance Overview: EVOK
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EVOK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EVOK
View MoreValuation Measures
Market Cap
4.71M
Enterprise Value
-3.73M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.59
Price/Book (mrq)
0.67
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-52.22%
Return on Assets (ttm)
-26.46%
Return on Equity (ttm)
-240.09%
Revenue (ttm)
10.25M
Net Income Avi to Common (ttm)
-5.35M
Diluted EPS (ttm)
-2.8100
Balance Sheet and Cash Flow
Total Cash (mrq)
13.6M
Total Debt/Equity (mrq)
73.32%
Levered Free Cash Flow (ttm)
-3.67M